BioSpace News Archive

Orchard Therapeutics, a global gene therapy leader, announced that the company’s chief executive officer, Bobby Gaspar, M.D., Ph.D., has been appointed to the Alliance for Regenerative Medicine’s 2021 board of directors.

Growing Patent Estate Creates Value and Supports Key Combination Therapies

NeuroMetrix, Inc. reported financial and business highlights for the quarter ended September 30, 2020.

Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced it received approval from the U.S. Food and Drug Administration to market Ephedrine Sulfate Injection in a ready-to-use 50mg/10 ml single use vial presentation.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced that the company will host a conference call and live webcast on Thursday, November 5, 2020 at 8:00 a.m. ET to report its third quarter 2020 financial results and other business highlights.

Adicet Bio, Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for ADI-001, an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor targeting CD20 for treatment of non-Hodgkin’s lymphoma.

Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease -- Lead clinical asset AZR-MD-001 for Meibomian gland dysfunction to advance through registration study -- Meibomian gland dysfunction is the leading cause of Dry Eye Disease, a condition known to affect more than 30 million adults in the United States alone

Reven Holdings, Inc. (“Reven”) is a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnesses—including COVID-19—and inflammatory disorders. Reven today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application in connection with its lead anti-inf

Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, today announced the appointment of Anu Hoey as Chief Business Officer, responsible for leading business and corporate development. “We are thrilled to welcome Anu to our team to help drive our strategic growth. Her business development e

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2020 financial results and business highlights. What: Vericel Corporation Third-Quarter 2020 Earnings Call When: Thursday, November 5, 2020 at 8:30am (EDT) Where: http://investors.vcel.com/events-presentations How: T